Study of ManNAc for kidney diseases with proteinuria
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called ManNAc for people with certain kidney diseases (FSGS, MCD, or MN) that cause protein in the urine. The goal is to see if this drug can help reduce protein loss and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy showing one of these conditions: FSGS, MCD, or MN, within the last 10 years.
- Your urine protein level must be high (at least 2 grams per gram of creatinine) on three separate tests.
- Your kidney function must be at a certain level (eGFR of at least 30).
- You must be at least 18 years old and weigh more than 50 kg (about 110 pounds).
- You must be willing to use effective birth control (if applicable) and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests a medicine called atacicept in adults and children with several types of kidney disease. The goal is to see if it can reduce protein in the urine and help protect kidney function.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.